To manage health related disorders better, customary drug research has penetrated the biotech space in areas such as synthesis and manipulation of gene and its products. It transforms the therapeutic products from pharmaceutical drugs to recombinant biologicals. It is important to discover and develop new therapies to meet strenuous medical challenges.

To discover contemporary remedies, it requires the support from computational biology and chemistry, genomics and proteomics to confirm and recognize drug targets.

Challenges faced by the Industry

The researchers need to analyze huge volume of data and deduce its relationship. It involves

• Labor- intensive work with high cost and time
• Data analysis and comparison needs more co-ordination.
• Multiple risks against success odds determine the launch probability at each node in the advancement of drug value chain.
• Errors in analysis are most common due to disparate systems
• Regulatory compliance

This demands laborious tasks like collecting the desired samples, storing, analyzing and recording the data after a series of experimental analysis.

Covansys Offerings

Covansys provides clinical development integration solutions to improve efficiency and shorten the cycle time of drug discovery. We provide scientific software solutions suited to customer requirements and help in optimization by way of –

• Increasing the efficiency of computational tools that hasten the process of drug discovery and development.
• Integrate clinical and scientific data to provide vital solutions that enhance the decision excellence in product development
• Secure operation of stored data with setting up of parameters, cost considerations, resources, time management, risks, percentage of errors, profit percentage and its maintenance for a specific in vitro research from wet lab portfolio to bioreactor kinetics and formulations during manufacturing process management
• Medical information systems for decision support with safety and security of sharing the data across the venture and to maintain regulatory compliance (21 CFR Part 11, GMP/cGMP and GLP/cGLP) through our domain and technical expertise

In the past, we have helped organizations to convert logical data into useful proprietary knowledge bank.